ACB · Aurora Cannabis Inc. · Stock research

Current Thesis

ACB is a sentiment-beta proxy on the U.S. cannabis-reschedule trade, and both the fundamental and structural legs have deteriorated since mid-June. Aurora is a Canadian licensed producer with no U.S. THC operations, so the economic catalyst the April 2026 medical rescheduling that killed 280E for U.S. medical operators does not accrue to it. The June 29–July 15 2026 DEA hearing on the broader Schedule-III proposal, the last live sentiment driver, opened with government counsel stating plainly that "this is not about recreational cannabis," and the seven DEA-selected participants all oppose rescheduling capping the read-through a Canadian LP would need. Layered on top, the June 11 Q4 print carried a FY2027 "reset year" guide: total net revenue expected to decline toward FY2025 levels on a ~30% cut to Canadian medical reimbursement effective April 1. The stock has since broken to a fresh $2.63 52-week low (last ~$2.71, July 10 close), roughly 59% below the $6.67 high. Broken-structure laggard into a neutered catalyst stand aside until it bases.

Bullish and bearish views on Aurora Cannabis Inc.

The model's bull view on Aurora Cannabis Inc. (ACB), in brief: International medical is the margin engine: Aurora is exiting lower-margin Canadian consumer and propagation and leaning into Germany/Poland; it acquired Safari Flower Company to expand EU GMP capacity (Q4/FY26 call, June 11 2026). The bear view: The catalyst does not pay this ticker. Medical rescheduling and 280E relief are U.S.-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). Government counsel's "this is not about recreational cannabis" (hearing, opened June 29 2026) removes the read-through a Canadian LP would… Both cases follow in full.

Bull Case

• International medical is the margin engine: Aurora is exiting lower-margin Canadian consumer and propagation and leaning into Germany/Poland; it acquired Safari Flower Company to expand EU GMP capacity (Q4/FY26 call, June 11 2026).
• FY2026 finished strong: trailing-twelve-month revenue $229.67M, +11% YoY; the June 11 2026 Q4 print beat on the top line ($61.842M vs $55.290M consensus) at a 64% adjusted gross margin.
• Net-cash balance sheet: after years of dilution and asset sales, the near-term solvency overhang that still dogs several peers is off the table.
• Sector sentiment optionality into a hard date: the DEA hearing runs through ~July 15 2026; any surprise scope-expansion toward recreational downscheduling would spike the whole complex and ACB catches beta.
• Sell-side still constructive on paper: consensus "Buy," average price target $6.16 stale, but a gap the tape would reprice if the story turned.

Bear Case

• The catalyst does not pay this ticker. Medical rescheduling and 280E relief are U.S.-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). Government counsel's "this is not about recreational cannabis" (hearing, opened June 29 2026) removes the read-through a Canadian LP would need.
• FY2027 is a guided step-down: total net revenue expected to decline toward FY2025 levels, adjusted EBITDA lower YoY, and adjusted gross margin easing to the mid-to-high 50s from 64% driven by the ~30% cut in Canadian medical reimbursement effective April 1 2026.
• Fresh 52-week low: the stock printed $2.63 and sits ~$2.71 (July 10 2026), below the prior $3.07 floor cited a month ago no higher-low base, mean-reversion-down geometry.
• Hearing stacked against: all seven DEA-designated participants oppose rescheduling (hearing coverage, late June 2026); a broad reschedule still faces formal rulemaking, comment and appeal risk even if the ALJ recommends it.
• Chronic dilution / reverse-split history: a sub-$3 heavy-retail float, market cap now ~$169M (down ~24%) an equity raise into any sentiment pop would cap upside.

Setup & Price Structure

• Last ~$2.71 (July 10 2026 close; after-hours $2.68). 52-week range $2.63–$6.67 roughly 59% below the high and pinned within ~3% of the low.
• The prior floor near $3.07 (cited mid-June) has been lost; the breakdown to $2.63 confirms the downtrend rather than forming a base.
• Below the 20-, 50- and 200-day moving averages, with no reclaim of the 50-DMA on volume the minimum bar for any event-driven re-engagement.
• Retail-squeeze profile (low-dollar, heavy-retail float, dilution/reverse-split history) argues for tight sizing on any probe; this is an event lottery the kind of setup that punishes size.
• Relative weakness intact: the U.S. operator complex (MSOS and peers) has led every sentiment pop while ACB stayed near its low the laggard, not the leader.

Catalyst Calendar (next 30 days)

• 2026-07 (ongoing): headline risk on any scope-expansion or recreational commentary entering the hearing record; sentiment-only for a Canadian LP.
• ~2026-09 (est.): next quarterly print (Q1 FY27) first actuals on the FY2027 reset. Outside the 30-day window.

Elapsed catalysts

• ~2026-07-15: DEA administrative rescheduling hearing scheduled to conclude (began June 29; ran ahead of schedule, with a one-day pause the week of July 6). Post-hearing briefs → ALJ recommendation → DEA final rule follow on a multi-month timeline no immediate binary for ACB. _(passed 4d ago)_

What Would Change Our Mind

• A weekly close back above the 50-DMA on expanding volume, reclaiming the lost ~$3.07 shelf, would flip this from broken-structure laggard to an event-driven re-engagement candidate.
• The DEA hearing record surfacing genuine recreational-downscheduling scope (beyond the medical framing government counsel confirmed) would restore the sector-beta thesis for Canadian LPs.
• FY2027 guidance revised upward or the Canadian reimbursement cut proving less severe than the ~30% flagged would remove the fundamental step-down that underwrites the bear case.
• An MSOS/U.S.-operator breakout that finally drags ACB above its moving averages, rather than leaving it pinned, would signal the sector beta is transmitting again.

Correlation Notes

• Trades as high-beta sector sentiment: correlated to MSOS, CGC, CRON and TLRY on reschedule headlines, but with a lower slope it lags on the way up and keeps pace on the way down.
• The economic winners of U.S. rescheduling are the MSOs (GTBIF, CURLF, TCNNF); ACB's move is derivative of their tape, not its own fundamentals.
• Idiosyncratic downside from Canadian reimbursement policy (April 1 2026 ~30% reimbursement cut) is uncorrelated to the U.S. reschedule trade a company-specific drag stacked on top of sector beta.
• Broad small-cap speculative flows amplify moves in both directions given the sub-$3 price and thin, retail-heavy float.